Charles River Laboratories International Inc(CRL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | - | EPS (ttm) | -4.85 | Insider Own | 1.12% | Shs Outstand | 47.7M | Perf Week | 19.08% |
| Market Cap | 17.06B | Forward P/E | 27.92 | EPS next Y | 12.45% | Insider Trans | -26.54% | Shs Float | 47.2M | Perf Month | 22% |
| Enterprise Value | 19.92B | PEG | 2.39 | EPS next Q | 2.97 | Inst Own | 123.18% | Short Float | 6.1% | Perf Quarter | 48.6% |
| Income | -0.24B | P/S | 4.27 | EPS this Y | 10.69% | Inst Trans | -2.01% | Short Ratio | 2.88 | Perf Half Y | 108.65% |
| Sales | 4.00B | P/B | 6 | EPS next 5Y | 11.7% | ROA | -3.16% | Short Interest | 2.88M | Perf YTD | 79.1% |
| Book/sh | 59.5 | P/C | 78.8 | EPS past 3/5Y | - | ROE | -7.7% | 52W High | 1.73% ($351.21) | Perf Year | 81.32% |
| Cash/sh | 4.53 | P/FCF | 46.02 | Sales past 3/5Y | 0.33% 6.55% | ROIC | -4.06% | 52W Low | 144.38% ($146.20) | Perf 3Y | 104.07% |
| Dividend Est. | - | EV/EBITDA | 23.77 | EPS Y/Y TTM | -268.79% | Gross Margin | 32.63% | Volatility(W/M) | 5.52% 4.31% | Perf 5Y | -16.88% |
| Dividend TTM | - | EV/Sales | 4.98 | Sales Y/Y TTM | -0.74% | Oper. Margin | 13.51% | ATR (14) | 13.47 | Perf 10Y | 358.1% |
| Dividend Ex-Date | - | Quick Ratio | 1.04 | EPS Q/Q | -102.91% | Profit Margin | -5.96% | RSI (14) | 76.4 | Recom | 1.85 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.35 | Sales Q/Q | -2.72% | SMA20 | 15.33% ($309.78) | Beta | 1.38 | Target Price | $331.29 |
| Payout | - | Debt/Eq | 1.07 | Earnings | 2026/11/4 | SMA50 | 20.91% ($295.48) | Rel Volume | 1.18 | Prev Close | $345.37 |
| Employees | 19700 | LT Debt/Eq | 1.07 | EPS/Sales Surpr. | 10.13% 2.75% | SMA200 | 63.27% ($218.82) | Avg Volume(3M) | 1.00M | Price | $357.27 |
| IPO | 2000/6/23 | Option/Short | Yes/Yes | Trades | 15673 | Volume | 1,176,395 | Change | 3.45% |
A global contract research organization (CRO) that supports the preclinical stage of new drug development. The company supports the entire early-stage research and development process for pharmaceutical and biotech companies, including research models, drug discovery, safety evaluation, and contract manufacturing, and is a healthcare services company with a leading global position in the preclinical CRO field.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded about as much as usual. That is 118% of its average volume.
Next earnings report: November 4
8 days to go.
CRL keeps an operating profit but posts a net loss
Of every $100 in sales, $13.51 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $427. Peers typically go for $665. Compared with its own 3-year average, it is 1339% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -16.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 123.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #15 of 44 in the industry
Based on market cap of $17B.
GH#12 Guardant Health Inc $23B PER - 
MEDP#13 Medpace Holdings Inc $19B PER 37.5 
RVTY#14 Revvity Inc $18B PER 76.2 CRL#15 Charles River Laboratories International Inc $17B PER - 
ICLR#16 Icon Plc $14B PER 333.6 
FAQ
What kind of company is CRL?
CRL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of CRL?
The market cap of CRL is approximately $17.1B, ranking 651 within its sector.
What is the 52-week high and low for CRL?
CRL has recorded a 52-week high of $351.21 and a low of $146.20.
